Corcept Therapeutics (CORT)
(Delayed Data from NSDQ)
$34.79 USD
+0.51 (1.49%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $34.77 -0.02 (-0.06%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$34.79 USD
+0.51 (1.49%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $34.77 -0.02 (-0.06%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Zacks News
Here's Why You Should Add ANI Pharmaceuticals (ANIP) to Your Portfolio
by Zacks Equity Research
ANI Pharmaceuticals (ANIP), a top-ranked stock, has a diverse portfolio of rare disease and generic medicines. Its Purified Cortrophin Gel is witnessing incremental sales in recent quarters.
J&J (JNJ) Seeks Approval for Bladder Cancer Drug in Europe
by Zacks Equity Research
J&J's (JNJ) erdafitinib is already marketed as Balversa in the United States for FGFR-altered metastatic UC. Balversa is approved by the FDA under the accelerated pathway.
Merck's (MRK) Ebola Vaccine Gets Approval for Kids in Europe
by Kinjel Shah
The European Commission approves Merck's (MRK) Ebola vaccine for use in children as young as one year.
Why Is Ionis Pharmaceuticals (IONS) Up 1.4% Since Last Earnings Report?
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Lisata (LSTA) Up on Positive Updates for Pancreatic Cancer Study
by Zacks Equity Research
Lisata's (LSTA) shares gain on a favorable outcome in interim futility analysis of its lead candidate, LSTA1, for pancreatic cancer.
Journey Medical (DERM) & Maruho Ink Deal for Qbrexza Asia Rights
by Zacks Equity Research
Journey Medical (DERM) enters into a second licensing agreement with Maruho to develop and commercialize Qbrexza to treat hyperhidrosis in certain Asian countries. The stock surges 18.4%.
Why Is Zoetis (ZTS) Down 1.3% Since Last Earnings Report?
by Zacks Equity Research
Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
J&J (JNJ) to End Pulmonary Hypertension Study on Opsumit
by Zacks Equity Research
The decision to end the CTEPH study on J&J's (JNJ) Opsumit (macitentan) was made at the recommendation of the study's independent DMC, following a pre-planned interim analysis.
Palisade (PALI) In-Licenses Rights for IBD Candidate, Stock Up
by Zacks Equity Research
Palisade (PALI) gains on entering into global licensing deal with Giiant Pharma to develop gastrointestinal therapies.
Theravance Bio (TBPH) Down 2.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Mirum Pharma (MIRM) Stock Rises 42% Year to Date: Here's Why
by Zacks Equity Research
Mirum Pharma (MIRM) surges 42% year to date due to encouraging progress in label-expansion efforts of Livmarli, along with strategic initiatives, to expand its commercial portfolio.
Amgen (AMGN) Stock Outperforms Industry YTD: Here's Why
by Zacks Equity Research
Amgen (AMGN) expects strong sales growth of products like Tezspire, Evenity and Repatha to be offset by lower revenues from oncology biosimilars and Enbrel.
AstraZeneca (AZN) Gets FDA CRL for Ultomiris in New Indication
by Zacks Equity Research
AstraZeneca (AZN) said the CRL for Ultomiris for NMOSD indication does not raise any concerns about the efficacy and safety data from the study.
Insmed (INSM) Up on Positive Data From MAC Lung Disease Study
by Zacks Equity Research
Insmed's (INSM) shares rise on positive data from the late-stage ARISE study evaluating Arikayce for newly infected lung disease caused by MAC.
AC Immune (ACIU) Surges 43% in the Past 3 Months: Here's Why
by Zacks Equity Research
AC Immune's (ACIU) shares rose 43% over the past three months, driven by rapid progress in the development of its pipeline candidate, ACI-24.060, for neurodegenerative diseases.
SCYNEXIS (SCYX) Skyrockets 134% Year to Date: Here's Why
by Zacks Equity Research
SCYNEXIS' (SCYX) shares soar 134% year to date, owing to partnership with big wig GSK plc for the development of its antifungal tablet, Brexafemme.
Centessa (CNTA) Surges 72% in the Past 3 Months: Here's Why
by Zacks Equity Research
Centessa (CNTA) shares rise significantly in the past three months due to the encouraging progress in the development of its lead pipeline candidate, SerpinPC, which is currently in mid-late-stage studies.
Why Is Corcept (CORT) Up 4.8% Since Last Earnings Report?
by Zacks Equity Research
Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Roche's (RHHBY) Late-Stage Lung Cancer Study Meets Primary Goal
by Zacks Equity Research
Roche's (RHHBY) late-stage ALK-positive non-small cell lung cancer study evaluating Alecensa meets the primary endpoint of disease-free survival.
Alkermes (ALKS) Grants Teva License to Market Generic Drug
by Zacks Equity Research
Alkermes (ALKS) grants Teva an exclusive license to market a generic version of Vivitrol in the United States, thereby resolving patent litigation. The stock of the company rises 7%.
Zai Lab (ZLAB) Up on Breakthrough Therapy Tag for Oncology Drug
by Zacks Equity Research
Zai Lab (ZLAB) gains on receiving Breakthrough Therapy designation for repotrectinib from the Center for Drug Evaluation of the National Medical Products Administration in China.
J&J (JNJ) Updates 2023 Guidance After Final Kenvue Separation
by Zacks Equity Research
With the complete separation of the Consumer Health segment, J&J (JNJ) is now a two-sector company focused on the Pharmaceutical and MedTech fields.
FibroGen (FGEN) Fails to Meet Goals in DMD Study, Stock Down 23%
by Zacks Equity Research
FibroGen (FGEN) falls 22.7% as its late-stage study of pamrevlumab for the treatment of ambulatory patients with Duchenne muscular dystrophy fails to meet the primary endpoint.
Vertex (VRTX) Outperforms Industry Year to Date: Here's Why
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) is expected to benefit from several catalysts this year. The company is likely to achieve multiple clinical milestones in 2023 and 2024, both in its CF and non-CF portfolio.
Axcella (AXLA) Up on Patent Grant for Long Covid Fatigue Drug
by Zacks Equity Research
Axcella (AXLA) shares surge 299% after the company secures a methods-of-use patent for its lead candidate, AXA1125, which is currently under development to treat fatigue associated with Long Covid.